Hesperidin Recovers Lipopolysaccharideinduced Preeclampsia-like Complications in Pregnant Rat Model

Background: Preeclampsia is a complex and multifactorial disorder that develops during pregnancy, defined by the onset of hypertension and proteinuria, often accompanied by other systemic manifestations. Objectives: The current study evaluated the beneficial effects of hesperidin against lipopolysaccharide (LPS)-induced preeclampsia model in pregnant rats. Materials and Methods: In this study, the pregnant rats were induced with experimental preeclampsia by treating them with 1.0 μg/kg of LPS and then treated with hesperidin. The changes in systolic blood pressure (SBP) and urinary protein/creatinine concentrations in the rats were measured. The concentrations of angiogenic biomarkers, inflammatory biomarkers, and lipid peroxidation markers were estimated using kits. Furthermore, the effect of hesperidin on the pregnancy outcomes in pregnant rats with preeclampsia was evaluated. Results: The result of this work indicated that hesperidin treatment effectively decreased the SBP and urinary protein/creatinine ratio and effectively regulated the changes in angiogenic biomarkers in pregnant rats with preeclampsia. Furthermore, the hesperidin treatment successfully diminished the inflammatory and oxidative stress biomarker levels and substantially improved the pregnancy outcomes in the pregnant rats with preeclampsia. Conclusion: In conclusion, the treatment of hesperidin in pregnant rats with preeclampsia improved the abnormal phenotypes and mitigated the complications. These data indicate that hesperidin can lessen the preeclampsia condition, suggesting that it may be further promoted as a possible therapeutic agent for preeclampsia.